CNST

CNST Stock Is Particularly Risky After Its Recent Run

By Josh Enomoto, InvestorPlace Contributor
Enjoying a blistering run within the last two months, CNST stock has quickly attracted eyeballs. But with such strong momentum, investors shouldn’t lose sight of the tough fundamental picture for pharmaceutical companies.

4 IPOs That Went Public in Q3 — Including Tilray

By Tom Taulli, InvestorPlace Contributor
Q3 showed that the market for IPOs remains in the bull phase. Here’s a look at some of the notable deals that went down.